Our results highlight the importance of the MQC system dysregulation in the pathological remodeling of cardiac hypertrophy caused by FARS2 deficiency and the potential therapeutic approaches in FARS2 or mtARS-associated cardiomyopathy. This evidence concerns the gene FARS2 and cardiac hypertrophy.